The only published cohort studies of r-hGH patients not originating from follow-up in a pharmaceutical company database have been of 360 cancer patients in the US followed for an unspecified period [28] and 289 hypopituitarism patients in Sweden followed for an average of 5 years [29]. The gene discussed is GH1; the disease is cancer.